Contact
Please use this form to send email to PR contact of this press release:
Ukoniq (umbralisib): Drug Safety Communication - FDA Approval of Lymphoma Medicine is Withdrawn Due to Safety Concerns
TO:
Please use this form to send email to PR contact of this press release:
Ukoniq (umbralisib): Drug Safety Communication - FDA Approval of Lymphoma Medicine is Withdrawn Due to Safety Concerns
TO: